Results 291 to 300 of about 2,860,326 (352)
ST6GAL1 plays a critical role in tumor progression and immune regulation in colorectal cancer (CRC). Its depletion significantly suppresses the malignant phenotype of CRC cells and enhances the efficacy of anti‐PD‐L1 therapy. High ST6GAL1 expression promotes an immune‐activated tumor microenvironment (TME), characterized by increased infiltration of ...
Ximo Xu+15 more
wiley +1 more source
Development of an Effective Single-Dose PCV2/CSFV Bivalent Subunit Vaccine Against Classical Swine Fever Virus and Porcine Circovirus Type 2. [PDF]
Chen YC+5 more
europepmc +1 more source
Current preclinical studies of AAV‐mediated gene therapy explore different strategies based on the characteristics of inner ear diseases. For genetic hearing loss, approaches include the replacement of a “good gene,” removal of a “bad gene,” or direct correction of mutations through base editing.
Fan Wu+7 more
wiley +1 more source
Development of an In-House Antigen ELISA Using Monoclonal and Polyclonal Antibodies Against an Isolated Canine Distemper Virus. [PDF]
Kökkaya S, Göksu AG.
europepmc +1 more source
Neutralizing Antibodies: Role in Immune Response and Viral Vector Based Gene Therapy. [PDF]
Tsaregorodtseva TS+8 more
europepmc +1 more source
Expression of BVDV E2 protein in CHO-S cells and development of an indirect ELISA for serological detection. [PDF]
Wang J, Zhang A, Hou Z, Tan B, Zhang S.
europepmc +1 more source
Recent Progress in the Vaccine Development Against Epstein-Barr Virus. [PDF]
Dai Y+5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Human Antibodies for Viral Infections
Annual Review of Immunology, 2022Antibodies have been used to prevent or treat viral infections since the nineteenth century, but the full potential to use passive immunization for infectious diseases has yet to be realized. The advent of efficient methods for isolating broad and potently neutralizing human monoclonal antibodies is enabling us to develop antibodies with unprecedented
J. Crowe
openaire +3 more sources